HRS-7535-202 Follow-up Study: A Long-term Evaluation of Safety, Tolerability, and Efficacy in Obese Subjects (Open-label, Extension Trial)
Latest Information Update: 20 Nov 2025
At a glance
- Drugs HRS-7535 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Shandong Suncadia Medicine
Most Recent Events
- 17 Nov 2025 Actual primary completion date changed to 15 Aug 2025.
- 17 Nov 2025 Status changed from active, no longer recruiting to completed.
- 10 Apr 2025 Status changed from not yet recruiting to active, no longer recruiting.